Lv1
26 积分 2023-12-11 加入
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
6天前
已完结
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
6天前
已完结
Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis
16天前
已完结
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
16天前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
18天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
25天前
已完结
Treatment advances across the cervical cancer spectrum
29天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
1个月前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
1个月前
已完结
皖公网安备34019202002308
